國家衛生研究院 NHRI:Item 3990099045/14706

NHRI > National Institute of Infectious Diseases and Vaccinology > Others > Periodical Articles > Item 3990099045/14706

Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/14706

Title:	Evolution of neutralizing antibodies and cross-activity against different variants of SARS-CoV-2 in patients recovering from COVID-19
Authors:	Liu, WD;Wang, JT;Chao, TL;Ieong, SM;Tsai, YM;Kuo, PH;Tsai, MJ;Chen, YJ;Li, GC;Ho, SY;Chen, HH;Huang, YS;Hung, CC;Chen, YC;Chang, SY;Chang, SC
Contributors:	National Institute of Infectious Diseases and Vaccinology
Abstract:	Background: Patients recovering from COVID-19 may need vaccination against SARS-CoV-2 because acquired immunity from primary infection may wane, given the emergence of new SARS-CoV-2 variants. Understanding the trends of anti-spike IgG and neutralizing antibody titers in patients recovering from COVID-19 may inform the decision made on the appropriate interval between recovery and vaccination. Methods: Participants aged 20 years or older and diagnosed with COVID-19 between January and December, 2020 were enrolled. Serum specimens were collected every three months from 10 days to 12 months after the onset of symptom for determinations of anti-spike IgG and neutralizing antibody titers against SARS-CoV-2 Wuhan strain with D614G mutation, alpha, gamma and delta variants. Results: Of 19 participants, we found a decreasing trend of geometric mean titers of anti-spike IgG from 560.9 to 217 and 92 BAU/mL after a 4-month and a 7-month follow-up, respectively. The anti-spike IgG titers declined more quickly in the ten participants with severe or critical disease than the nine participants with only mild to moderate disease between one month and seven months after SARS-CoV-2 infection (−8.49 vs - 2.34-fold, p < 0.001). The neutralizing activity of the convalescent serum specimens collected from participants recovering from wild-type SARS-CoV-2 infection against different variants was lower, especially against the delta variants (p < 0.01 for each variant with Wuhan strain as reference). Conclusion: Acquired immunity from primary infection with SARS-CoV-2 waned within 4–7 months in COVID-19 patients, and neutralizing cross-activities against different SARS-CoV-2 variants were lower compared with those against wild-type strain.
Date:	2023-08
Relation:	Journal of the Formosan Medical Association. 2023 Aug;122(8):714-722.
Link to:	http://dx.doi.org/10.1016/j.jfma.2022.11.015
JIF/Ranking 2023:	http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0929-6646&DestApp=IC2JCR
Cited Times(WOS):	https://www.webofscience.com/wos/woscc/full-record/WOS:001050339000001
Cited Times(Scopus):	https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85143882331
Appears in Collections:	[Others] Periodical Articles

Files in This Item:

File	Description	Size	Format
SCP85143882331.pdf		985Kb	Adobe PDF	127	View/Open

Loading...